Gland Pharma Reports Strong Financial Results, Indicating Positive Growth Trajectory in August 2025
Gland Pharma recently announced its financial results for the quarter ending June 2025, showcasing significant achievements. The company reported its highest Profit Before Tax at Rs 255.21 crore and net sales of Rs 1,505.62 crore. Additionally, Profit After Tax reached Rs 215.48 crore, reflecting strong operational performance.
Gland Pharma, a small-cap player in the Pharmaceuticals & Biotechnology industry, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 5, 2025, indicate a notable shift in the company's evaluation, with its score reflecting a significant adjustment from the previous period.The financial data reveals that Gland Pharma achieved its highest Profit Before Tax less Other Income (PBT) at Rs 255.21 crore, marking a positive trend over the last five quarters. Additionally, net sales reached Rs 1,505.62 crore, also the highest in the same timeframe, suggesting a robust sales performance. The Operating Profit (PBDIT) stood at Rs 367.76 crore, further underscoring the company's operational strength.
Moreover, the Profit After Tax (PAT) was recorded at Rs 215.48 crore, which is the highest in the last five quarters and reflects a healthy growth rate compared to previous averages. The Earnings per Share (EPS) also reached a peak of Rs 13.08, indicating enhanced profitability for shareholders.
Overall, Gland Pharma's recent financial results highlight a positive trajectory in key performance metrics, leading to a revision in its score.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
